Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04765111
Title Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center

mantle cell lymphoma


Acalabrutinib + Rituximab

Age Groups: senior
Covered Countries USA

No variant requirements are available.